Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105236

1.

New Activity of a Protein from Canavalia ensiformis.

Bogoeva VP, Petrova LP, Trifonov AA.

Sci Pharm. 2014 Jun 16;82(4):825-34. doi: 10.3797/scipharm.1404-09. eCollection 2014 Dec.

2.

Selective use of vandetanib in the treatment of thyroid cancer.

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.

Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review.

3.

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

Medina-Sanson A, Ramírez-Pacheco A, Moreno-Guerrero SS, Dorantes-Acosta EM, Sánchez-Preza M, Reyes-López A.

Biomed Res Int. 2015;2015:309491. doi: 10.1155/2015/309491. Epub 2015 May 18.

4.

Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic.

Quiñones LA, Lee KS.

Front Genet. 2015 Jun 3;6:195. doi: 10.3389/fgene.2015.00195. eCollection 2015. No abstract available.

5.

Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review.

Rigon RB, Oyafuso MH, Fujimura AT, Gonçalez ML, do Prado AH, Gremião MP, Chorilli M.

Biomed Res Int. 2015;2015:841817. Epub 2015 May 11. Review.

6.

Targeted therapies for ER+/HER2- metastatic breast cancer.

Yamamoto-Ibusuki M, Arnedos M, André F.

BMC Med. 2015 Jun 9;13:137. doi: 10.1186/s12916-015-0369-5. Review.

7.

Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Papanagnou P, Baltopoulos P, Tsironi M.

Ther Clin Risk Manag. 2015 May 18;11:807-19. doi: 10.2147/TCRM.S82049. eCollection 2015. Review.

8.

Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.

Ediriwickrema A, Saltzman WM.

ACS Biomater Sci Eng. 2015 Feb 9;1(2):64-78. Epub 2015 Jan 13. Review.

9.

Gold(III)-pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents.

Nardon C, Chiara F, Brustolin L, Gambalunga A, Ciscato F, Rasola A, Trevisan A, Fregona D.

ChemistryOpen. 2015 Apr;4(2):183-91. doi: 10.1002/open.201402091. Epub 2015 Feb 19.

10.

Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.

Hayano K, Lee SH, Sahani DV.

Indian J Radiol Imaging. 2015 Apr-Jun;25(2):121-8. doi: 10.4103/0971-3026.155835.

11.

The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.

Sato A.

Onco Targets Ther. 2015 Apr 8;8:761-8. doi: 10.2147/OTT.S79776. eCollection 2015. Review.

12.

CCMCL1: a new model of aggressive mantle cell lymphoma.

Zhao X, Chen-Kiang S, Shetty S, Di Liberto M, Bodo J, Durkin L, Eng K, Elemento O, Smith MR, Hsi ED.

Blood. 2015 Apr 23;125(17):2730-2. doi: 10.1182/blood-2015-01-622795. No abstract available.

13.

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.

Sakamoto K, Yokogawa T, Ueno H, Oguchi K, Kazuno H, Ishida K, Tanaka N, Osada A, Yamada Y, Okabe H, Matsuo K.

Int J Oncol. 2015 Jun;46(6):2327-34. doi: 10.3892/ijo.2015.2974. Epub 2015 Apr 20.

14.

Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

McMahon KM, Foit L, Angeloni NL, Giles FJ, Gordon LI, Thaxton CS.

Cancer Treat Res. 2015;166:129-50. doi: 10.1007/978-3-319-16555-4_6. Review.

15.

Clinical and microbiological profiles of shigellosis in children.

Sangeetha AV, Parija SC, Mandal I, Krishnamurthy S.

J Health Popul Nutr. 2014 Dec;32(4):580-6.

16.

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.

Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I.

Br J Cancer. 2015 Apr 28;112(9):1428-34. doi: 10.1038/bjc.2015.103. Epub 2015 Apr 16.

17.

Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.

Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM.

Tex Heart Inst J. 2015 Apr 1;42(2):124-30. doi: 10.14503/THIJ-14-4509. eCollection 2015 Apr.

18.

Comprehensive review on betulin as a potent anticancer agent.

Król SK, Kiełbus M, Rivero-Müller A, Stepulak A.

Biomed Res Int. 2015;2015:584189. doi: 10.1155/2015/584189. Epub 2015 Mar 19. Review.

19.

SCARB2/LIMP-2 Regulates IFN Production of Plasmacytoid Dendritic Cells by Mediating Endosomal Translocation of TLR9 and Nuclear Translocation of IRF7.

Guo H, Zhang J, Zhang X, Wang Y, Yu H, Yin X, Li J, Du P, Plumas J, Chaperot L, Chen J, Su L, Liu Y, Zhang L.

J Immunol. 2015 May 15;194(10):4737-49. doi: 10.4049/jimmunol.1402312. Epub 2015 Apr 10.

20.

Anticancer Effect of AntiMalarial Artemisinin Compounds.

Das AK.

Ann Med Health Sci Res. 2015 Mar-Apr;5(2):93-102. doi: 10.4103/2141-9248.153609. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk